Harmony Bio Q1 WAKIX revenue $119.1M (+40% YoY); GAAP EPS $0.48; patients ~5,200

Harmony Biosciences Holdings, Inc.

2023-Q1 EPS reported $0.48 revenue$119,126,000

Net product revenue $119.1M, +39.6% YoY; GAAP net income $29.5M ($0.48 diluted EPS) vs $21.5M ($0.35) prior year.
Average patients on WAKIX ~5,100 (+1,200 YoY); exited Q1 with ~5,200 patients.
Cumulative WAKIX net revenue surpassed $1B since launch; Phase 3 IH INTUNE topline data expected Q4 2023.
Non-GAAP adjusted net income $40.1M ($0.66 diluted EPS) vs $31.1M ($0.51) prior year.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Harmony Biosciences Holdings, Inc. reported quarter ended March 31, 2023 results: revenue $119.1 million, net income $29.5 million, EPS $0.48.

Period: quarter ended March 31, 2023
Revenue: $119.1 million
Net income: $29.5 million
EPS: $0.48
Result: reported results

Exact text from the filing

--- ‌ Exhibit 99.1 HARMONY BIOSCIENCES REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS AND BUSINESS UPDATES WAKIX® (pitolisant) Net Revenue Increased ~40% Year-over-Year to $119.1 Million for First Quarter 2023 Average Number of Patients on WAKIX Increased ~1,200 Year-over-Year to ~5,100 for First Quarter 2023 Exited First Quarter 2023 With ~5,200 Patients on

View on SEC.gov

Browse all earnings releases →

Harmony Biosciences Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-23-007566

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.